Royalty Pharma reported Q3 2026 results with 9% growth in Royalty Receipts and raised full-year guidance. The company executed $1.6 billion in capital deployment and announced $1.9 billion in transaction value, driven by robust pipeline activity.
Royalty Pharma reported Q3 2026 results with 9% growth in Royalty Receipts and raised full-year guidance. The company executed $1.6 billion in capital deployment and announced $1.9 billion in transaction value, driven by robust pipeline activity.